KRAS Inhibitors Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines

DelveInsight's "KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the KRAS Inhibitors, historical and forecasted epidemiology as well as the KRAS Inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the KRAS Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; KRAS Inhibitors Market Forecast
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the KRAS Inhibitors Market Report:
• The KRAS Inhibitors market size was valued ~USD 475 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2024, Bristol Myers Squibb reported that the US FDA has granted priority review status to the supplemental New Drug Application (sNDA) for KRAZATI in combination with cetuximab for the treatment of KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.
• In January 2024, The European Commission provided conditional approval for KRAZATI to treat advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation, specifically for patients who have experienced disease progression after receiving at least one previous systemic therapy.
• In 2024, the total KRAS-mutated cases across the 7MM exceeded ~509,700 and are expected to rise throughout the forecast period.
• Among the analyzed cancer types, KRAS mutations are most prevalent in colorectal cancer (CRC), followed by pancreatic cancer, NSCLC, and LGSOC. In the U.S. alone, approximately ~66,000 KRAS-mutant CRC cases were reported in 2024.
• G12C is the most commonly detected KRAS mutation in NSCLC. Meanwhile, G12D is the predominant KRAS variant in colorectal cancer (CRC), pancreatic cancer, and LGSOC. In the U.S., KRASG12C accounts for around 37% of NSCLC cases, while KRASG12D occurs in approximately 42% of pancreatic cancer cases, 30% of CRC cases, and 42% of LGSOC cases.
• Among the approved KRAS inhibitor therapies, AVMAPKI + FAKZYNJA is anticipated to hold a larger market share than KRAZATI and LUMAKRAS during the forecast period (2020-2034).
• Key KRAS Inhibitors Companies: Amgen, Bristol Myers Squibb (Mirati Therapeutics), Verastem Oncology, Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, and others
• Key KRAS Inhibitors Therapies: LUMAKRAS/LUMYKRAS (sotorasib), KRAZATI (adagrasib), AVMAPKI + FAKZYNJA Co-Pack (avutometinib + defactinib), JDQ443, Avutometinib, BI 1701963, GDC-6036, LY353798, RMC-4630, and others
• The KRAS Inhibitors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage KRAS Inhibitors pipeline products will significantly revolutionize the KRAS Inhibitors market dynamics.

KRAS Inhibitors Overview
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of mutated KRAS proteins, which are commonly found in cancers like non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer. KRAS mutations, especially variants like G12C and G12D, drive uncontrolled cell growth. By targeting these mutations, KRAS inhibitors help slow tumor progression and improve treatment outcomes. Approved drugs such as LUMAKRAS and KRAZATI represent major advancements in treating KRAS-mutant cancers, with ongoing research exploring combination therapies and broader applications across cancer types.

Get a Free sample for the KRAS Inhibitors Market Report
https://www.delveinsight.com/report-store/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

KRAS Inhibitors Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

KRAS Inhibitors Epidemiology Segmentation:
The KRAS Inhibitors market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of KRAS Inhibitors
• Prevalent Cases of KRAS Inhibitors by severity
• Gender-specific Prevalence of KRAS Inhibitors
• Diagnosed Cases of Episodic and Chronic KRAS Inhibitors
Download the report to understand which factors are driving KRAS Inhibitors epidemiology trends @ KRAS Inhibitors Epidemiology Forecast
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

KRAS Inhibitors Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the KRAS Inhibitors market or expected to get launched during the study period. The analysis covers KRAS Inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the KRAS Inhibitors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

KRAS Inhibitors Therapies and Key Companies
• LUMAKRAS/LUMYKRAS (sotorasib): Amgen
• KRAZATI (adagrasib): Bristol Myers Squibb (Mirati Therapeutics)
• AVMAPKI + FAKZYNJA Co-Pack (avutometinib + defactinib): Verastem Oncology
• JDQ443: Novartis
• Avutometinib: Verastem Oncology
• BI 1701963: Boehringer Ingelheim
• GDC-6036: Roche
• LY353798: Eli Lilly
• RMC-4630: Revolution Medicines

Discover more about therapies set to grab major KRAS Inhibitors market share @ KRAS Inhibitors Treatment Market
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

KRAS Inhibitors Market Strengths
• Combining KRAS-targeted therapies with other treatment modalities, such as immunotherapies or traditional chemotherapy, holds promise for improving treatment outcomes. The potential for combination therapies creates additional market opportunities and enhances the overall market strength of KRAS mutations.

KRAS Inhibitors Market Opportunities
• To enhance the effectiveness of KRASG12C inhibitors in NSCLC, it is crucial to integrate them into the first-line standard of care(SOC). Nevertheless, the currently available agents have encountered difficulties due to toxic side effects when combined with anti-PD-(L)1 therapy.

Scope of the KRAS Inhibitors Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key KRAS Inhibitors Companies: Amgen, Bristol Myers Squibb (Mirati Therapeutics), Verastem Oncology, Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, and others
• Key KRAS Inhibitors Therapies: LUMAKRAS/LUMYKRAS (sotorasib), KRAZATI (adagrasib), AVMAPKI + FAKZYNJA Co-Pack (avutometinib + defactinib), JDQ443, Avutometinib, BI 1701963, GDC-6036, LY353798, RMC-4630, and others
• KRAS Inhibitors Therapeutic Assessment: KRAS Inhibitors current marketed and KRAS Inhibitors emerging therapies
• KRAS Inhibitors Market Dynamics: KRAS Inhibitors market drivers and KRAS Inhibitors market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• KRAS Inhibitors Unmet Needs, KOL's views, Analyst's views, KRAS Inhibitors Market Access and Reimbursement

To know more about KRAS Inhibitors companies working in the treatment market, visit @ KRAS Inhibitors Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. KRAS Inhibitors Market Report Introduction
2. Executive Summary for KRAS Inhibitors
3. SWOT analysis of KRAS Inhibitors
4. KRAS Inhibitors Patient Share (%) Overview at a Glance
5. KRAS Inhibitors Market Overview at a Glance
6. KRAS Inhibitors Disease Background and Overview
7. KRAS Inhibitors Epidemiology and Patient Population
8. Country-Specific Patient Population of KRAS Inhibitors
9. KRAS Inhibitors Current Treatment and Medical Practices
10. KRAS Inhibitors Unmet Needs
11. KRAS Inhibitors Emerging Therapies
12. KRAS Inhibitors Market Outlook
13. Country-Wise KRAS Inhibitors Market Analysis (2020-2034)
14. KRAS Inhibitors Market Access and Reimbursement of Therapies
15. KRAS Inhibitors Market Drivers
16. KRAS Inhibitors Market Barriers
17. KRAS Inhibitors Appendix
18. KRAS Inhibitors Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

KRAS Inhibitors Epidemiology https://www.delveinsight.com/report-store/kras-inhibitors-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'KRAS Inhibitors Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted KRAS Inhibitors epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.